Kerk, Samuel A. http://orcid.org/0000-0001-9786-2245
Papagiannakopoulos, Thales
Shah, Yatrik M. http://orcid.org/0000-0002-2487-4816
Lyssiotis, Costas A. http://orcid.org/0000-0001-9309-6141
Article History
Accepted: 28 May 2021
First Online: 9 July 2021
Competing interests
: T.P. has received honoraria and consulting fees from Calithera Biosciences and research support from Dracen Pharmaceuticals and Agios Pharmaceuticals. C.A.L. has received consulting fees from Astellas Pharmaceuticals and is an inventor on patents pertaining to KRAS-regulated metabolic pathways, redox control pathways in pancreatic cancer and targeting the GOT1 pathway as a therapeutic approach. Y.M.S. and S.A.K. have no competing interests to declare.